Arcus Biosciences announced that quemliclustat, an investigational small-molecule CD73 inhibitor, was granted orphan drug designation by the U.S. Food and Drug Administration to treat pancreatic cancer. Orphan drug designation is intended to support the development and evaluation of new treatments for rare diseases affecting fewer than 200,000 people in the United States.  This designation qualifies sponsors for incentives, including tax credits for qualified clinical trials, exemptio...